EUVIMEDEUVIMED entdecken
Open Access

Siglec-9 is an inhibitory receptor on human mast cells in vitro

Irina Miralda, Nyssa B Samanas, Albert J Seo, Jake S Foronda, Josie Sachen, Yvonne Hui, Shane D Morrison, Carole A Oskeritzian, Adrian M Piliponsky

Journal of Allergy and Clinical Immunology · 2023-09 · 152 (3) · 711-724.e14

DOI: 10.1016/j.jaci.2023.04.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-09. Verfasst von Irina Miralda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Wash. Hauptthemen laut MEDLINE: Mast Cells, Hyaluronic Acid. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIH HHS, Seattle Children's Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mast cell activation is critical for the development of allergic diseases. Ligation of sialic acid-binding immunoglobin-like lectins (Siglecs), such as Siglec-6, -7, and -8 as well as CD33, have been shown to inhibit mast cell activation. Recent studies showed that human mast cells express Siglec-9, an inhibitory receptor also expressed by neutrophils, monocytes, macrophages, and dendritic cells. OBJECTIVE: We aimed to characterize Siglec-9 expression and function in human mast cells in vitro. METHODS: We assessed the expression of Siglec-9 and Siglec-9 ligands on human mast cell lines and human primary mast cells by real-time quantitative PCR, flow cytometry, and confocal microscopy. We used a clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) gene editing approach to disrupt the SIGLEC9 gene. We evaluated Siglec-9 inhibitory activity on mast cell function by using native Siglec-9 ligands, glycophorin A (GlycA), and high-molecular-weight hyaluronic acid, a monoclonal antibody against Siglec-9, and coengagement of Siglec-9 with the high-affinity receptor for IgE (FcεRI). RESULTS: Human mast cells express Siglec-9 and Siglec-9 ligands. SIGLEC9 gene disruption resulted in increased expression of activation markers at baseline and increased responsiveness to IgE-dependent and IgE-independent stimulation. Pretreatment with GlycA or high-molecular-weight hyaluronic acid followed by IgE-dependent or -independent stimulation had an inhibitory effect on mast cell degranulation. Coengagement of Siglec-9 with FcεRI in human mast cells resulted in reduced degranulation, arachidonic acid production, and chemokine release. CONCLUSIONS: Siglec-9 and its ligands play an important role in limiting human mast cell activation in vitro.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mast CellsHyaluronic AcidHumansLigandsSialic Acid Binding Immunoglobulin-like LectinsImmunoglobulin E

Stichwörter der Autor:innen

CRISPR-Cas9FcεRIMast cellsSiglec-9sialic acids

Substanzen

LigandsHyaluronic AcidSialic Acid Binding Immunoglobulin-like LectinsImmunoglobulin E

Autor:innen und Institutionen

  • Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Wash.
  • University of South Carolina School of Medicine, Columbia, SC.
  • Department of Surgery, Division of Plastic Surgery, Seattle Children's Hospital, Seattle, Wash.
  • Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, Wash; Department of Pediatrics, University of Washington School of Medicine, Seattle, Wash; Department of Pathology, University of…

Förderung

  • NIGMS NIH HHS
  • NIH HHS
  • Seattle Children's Research Institute
  • National Institutes of Health
  • National Institute of General Medical Sciences

Zitieren

APA

Miralda, I., Samanas, N. B., Seo, A. J., Foronda, J. S., Sachen, J., Hui, Y., Morrison, S. D., Oskeritzian, C. A., & Piliponsky, A. M. (2023). Siglec-9 is an inhibitory receptor on human mast cells in vitro. Journal of Allergy and Clinical Immunology, 152(3), 711-724.e14. https://doi.org/10.1016/j.jaci.2023.04.007

Vancouver

Miralda I, Samanas NB, Seo AJ, Foronda JS, Sachen J, Hui Y, et al. Siglec-9 is an inhibitory receptor on human mast cells in vitro. Journal of Allergy and Clinical Immunology. 2023;152(3):711-724.e14. doi:10.1016/j.jaci.2023.04.007

BibTeX
@article{Miralda2023,
  author = {Miralda, Irina and Samanas, Nyssa B and Seo, Albert J and Foronda, Jake S and Sachen, Josie and Hui, Yvonne and Morrison, Shane D and Oskeritzian, Carole A and Piliponsky, Adrian M},
  title = {Siglec-9 is an inhibitory receptor on human mast cells in vitro},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2023},
  volume = {152},
  number = {3},
  pages = {711--724.e14},
  doi = {10.1016/j.jaci.2023.04.007}
}
Kostenlos starten →